Hofstra Northwell School of Medicine Residency Program in Internal Medicine
The program is the main clinical teaching site for the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell (formerly the Hofstra Northwell School of Medicine). Established in 2011 and having already graduated its second class, it is the first new allopathic medical school in New York state in more than 50 years, and has already been recognized for its innovative curriculum and didactic methodology.
In the spring of 2012, the residency program underwent regularly scheduled accreditation review by the ACGME Residency Review Committee. The result was the best possible outcome: continued accreditation, with the next scheduled review in 2022.
Department of Medicine faculty members have expertise in a wide range of research, with special emphasis on evidence-based medicine, healthcare delivery, and outcomes research. With more than 800 scientists, Northwell Health’s Feinstein Institute for Medical Research is among the top 5 percent of institutions that receive funding from National Institutes of Health. It provides unique opportunities for interaction with elite researchers and offers courses free of charge to housestaff.
Scholarly project timeline
Mentees will follow a structured three-year program timeline. Individualized project and training timelines will be developed with the mentee and mentor. Evaluations with the mentor and residency program director will be performed to assess research progress and adherence to personalized program timeline.
For a sample resident timeline, click here
View our trainees’ scholarly activity in the Lawrence Scherr Scholarly Activity Award book here.
The Lawrence Scherr Scholarly Activity Award is one of many ways that the Department of Medicine lives out its commitment to the role of excellence in training and education in academic medicine.
Dr. Scherr, who died in September 2012, was fully committed to breaking new ground in all 3 missions of academic medicine. Dr. Scherr was the founding chair of the Department of Medicine and is often considered the father of North Shore University Hospital. Dr. Scherr was an outstanding leader, educator, and colleague and touched the lives of countless trainees and patients over the many years he led our department. He established our residency training program and many of our fellowship programs. He retired in 2010 as the health system's official historian and Betsey Cushing Whitney Academic Dean Emeritus. The tone he set, the discipline and ethics he brought, his academic and clinical vision – all paved the way for a new medical school and a world-class research enterprise, now indispensable parts of Northwell Health.
The awards named for him carry on his tradition of academic excellence as they honor up-and-coming trainees with extraordinary academic accomplishments.
Following completion of my undergraduate degree, I accepted a position at the Children’s Hospital of Philadelphia where I served for ten years as Senior Research Scientist and Coordinator for Familial Neuroblastoma Studies. My fondest project during these years of study involved the discovery of ALK as the familial neuroblastoma predisposition gene. I began this project on the first day of my employment and, for the first several years, success seemed impossible. The development of SNP arrays, however, dramatically shifted the trajectory of our work. We engineered an international collaboration that allowed for the largest study of familial neuroblastoma patients to date. Only through this intensive collaboration were we able to make a discovery that would elucidate the source of disease for families who struggle with neuroblastoma. We were subsequently able to develop targeted therapies for neuroblastoma and, quite unexpectedly, reveal complex genetic pathways in other pediatric and adult cancers. A number of these rare cancers now experience high cure rates with the use of ALK therapies.
maintain an intense interest in translational medicine and am currently working with the Hepatology and Infectious Disease Departments on the effects of probiotic on inflammatory marker profiles in patients with Nonalcoholic Fatty Liver Disease (NAFLD).